Therefore, targeting the epigenetic changes induced by IDH mutations might be beneficial for chondrosarcoma patients, and could potentially help to overcome the intrinsic chemotherapy resistance in chondrosarcoma. This evidence concerns the gene IDH1 and chondrosarcoma.